Jane F. Apperley
YOU?
Author Swipe
View article: Changes in Common Blood Parameters After Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukaemia
Changes in Common Blood Parameters After Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukaemia Open
View article: BCR::ABL1 evaluation in bone marrow is no more predictive of TFR success than from peripheral blood
BCR::ABL1 evaluation in bone marrow is no more predictive of TFR success than from peripheral blood Open
Background Despite the excellent survival for chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI), most CML patients report poorer quality of life due to TKI side-effects. In the DESTINY trial ( NCT0180498…
View article: 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia Open
View article: Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL Open
The efficacy of and disease control afforded by tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia in chronic phase (CML-CP) have led to increased longevity and thus the continued pursuit of alternative therapies that are effica…
View article: A novel CIP2A and BCL-XL clinical diagnostic toolkit to predict disease progression and treatment-free remission in chronic myeloid leukaemia.
A novel CIP2A and BCL-XL clinical diagnostic toolkit to predict disease progression and treatment-free remission in chronic myeloid leukaemia. Open
Biomarkers that predict disease progression and treatment-free remission (TFR) would be of significant clinical value in chronic myeloid leukaemia (CML). We have previously shown that CIP2A levels at diagnosis can identify patients at incr…
View article: Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study
Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study Open
Rationale: Imatinib, 400 mg daily, reduces pulmonary vascular resistance and improves exercise capacity in patients with pulmonary arterial hypertension. Concerns about safety and tolerability limit its use. Objectives: We so…
View article: Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry
Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry Open
View article: Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy Open
View article: Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials Open
View article: Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia
Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia Open
Bosutinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia (CML), and for patients with Ph + chronic phase…
View article: Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score
Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score Open
Background The therapeutic landscape of chronic myeloid leukaemia (CML) has been transformed by tyrosine kinase inhibitors (TKI). Nilotinib, showed higher rates of major molecular response than imatinib, however associated with higher card…
View article: Is there really an accelerated phase of chronic myeloid leukaemia?
Is there really an accelerated phase of chronic myeloid leukaemia? Open
View article: Expectations and outcomes of varying treatment strategies for <scp>CML</scp> presenting during pregnancy
Expectations and outcomes of varying treatment strategies for <span>CML</span> presenting during pregnancy Open
Summary Diagnosing chronic myeloid leukaemia (CML) during pregnancy is rare. Tyrosine kinase inhibitors (TKIs) have traditionally been contraindicated owing to their teratogenicity. Management decisions should consider the risks to mother …
View article: Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia
Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia Open
Advancements in the management of patients with chronic myeloid leukemia (CML) allowed them to achieve survival comparable with their healthy counterparts. Consequently, their care has widened with growing focus on quality of life, includi…
View article: Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT
Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT Open
Summary Allogeneic haematopoietic cell transplantation (allo‐HCT) remains an option for tyrosine kinase inhibitor‐resistant chronic myeloid leukaemia (CML) in first chronic phase (CP1) and high‐risk patients with advanced disease phases. I…
View article: Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance Open
View article: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry Open
View article: Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma
Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma Open
View article: Richard Szydlo, July 1 1959–December 18 2023
Richard Szydlo, July 1 1959–December 18 2023 Open
View article: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials Open
Ponatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, and induced robust and durable…
View article: Project Confirm: Accelerated Drug Approvals for CML—Response
Project Confirm: Accelerated Drug Approvals for CML—Response Open
We thank Beumer and Salamone for their interest in our perspective piece (1). We note that they agree with our assertion that it is unlikely most patients with chronic myeloid leukemia (CML) require the maximum tolerated dose (MTD) of tyro…
View article: The EBMT: History, Present, and Future
The EBMT: History, Present, and Future Open
“Only he/she who knows the past has a future” is a proverb attributed to Wilhelm von Humboldt (1767–1835), a great historian, scientist, and philosopher (Spier, Big history and the future of humanity, Wiley, Chichester, 2015). It appears a…
View article: Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group
Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group Open
Chronic myeloid leukemia (CML) is characterized by leukocytosis with left-shifted neutrophilia, basophilia, eosinophilia, and variable thrombocytosis. However, extremely rare cases of patients with CML without significant leukocytosis and …
View article: European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia Open
From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential assessment of levels of residual disease and investigation of p…
View article: Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT) Open
View article: CML-398 Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study
CML-398 Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study Open
View article: POSTER: CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial
POSTER: CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial Open
View article: POSTER: CML-398 Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study
POSTER: CML-398 Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study Open
View article: CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial
CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial Open
View article: CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib Open